Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis

Affiliations

01 December 2016

-

doi: 10.1136/jnnp-2016-314013


Abstract

Background: Age at onset (AAO) in multiple sclerosis (MS) is an important marker of disease severity and may have prognostic significance. Understanding what factors can influence AAO may shed light on the aetiology of this complex disease, and have applications in the diagnostic process.

Methods: The study cohort of 22 162 eligible patients from 21 countries was extracted from the MSBase registry. Only patients with MS aged ≥16 years were included. To reduce heterogeneity, only centres of largely European descent were included for analysis. AAO was defined as the year of the first symptom suggestive of inflammatory central nervous system demyelination. Predictors of AAO were evaluated by linear regression.

Results: Compared with those living in lower latitudes (19.0-39.9°), onset of symptoms was 1.9 years earlier for those at higher latitudes (50.0-56.0°) (p=3.83×10-23). A reciprocal relationship was seen for ambient ultraviolet radiation (UVR), with a significantly increasing AAO for patients with MS per each quartile increment of ambient UVR (p=1.56×10-17). We found that the AAO of female patients was ∼5 months earlier than male patients (p=0.002). AAO of progressive-onset patients with MS were ∼9 years later than relapsing-onset patients (p=1.40×10-265).

Conclusions: An earlier AAO in higher latitude regions was found in this worldwide European-descent cohort and correlated inversely with variation in latitudinal UVR. These results suggest that environmental factors which act at the population level may significantly influence disease severity characteristics in genetically susceptible populations.


Similar articles

Seasonal variation of relapse rate in multiple sclerosis is latitude dependent.

Spelman T, Gray O, Trojano M, Petersen T, Izquierdo G, Lugaresi A, Hupperts R, Bergamaschi R, Duquette P, Grammond P, Giuliani G, Boz C, Verheul F, Oreja-Guevara C, Barnett M, Grand'Maison F, Edite Rio M, Lechner-Scott J, Van Pesch V, Fernandez Bolanos R, Flechter S, Den Braber-Moerland L, Iuliano G, Amato MP, Slee M, Cristiano E, Saladino ML, Paine M, Vella N, Kasa K, Deri N, Herbert J, Moore F, Petkovska-Boskova T, Alroughani R, Savino A, Shaw C, Vucic S, Santiago V, Bacile EA, Skromne E, Poehlau D, Cabrera-Gomez JA, Lucas R, Butzkueven H.Ann Neurol. 2014 Dec;76(6):880-90. doi: 10.1002/ana.24287. Epub 2014 Oct 20.PMID: 25283272

Geographical variations in sex ratio trends over time in multiple sclerosis.

Trojano M, Lucchese G, Graziano G, Taylor BV, Simpson S Jr, Lepore V, Grand'maison F, Duquette P, Izquierdo G, Grammond P, Amato MP, Bergamaschi R, Giuliani G, Boz C, Hupperts R, Van Pesch V, Lechner-Scott J, Cristiano E, Fiol M, Oreja-Guevara C, Saladino ML, Verheul F, Slee M, Paolicelli D, Tortorella C, D'Onghia M, Iaffaldano P, Direnzo V, Butzkueven H; MSBase Study Group and the New Zealand MS Prevalence Study Group.PLoS One. 2012;7(10):e48078. doi: 10.1371/journal.pone.0048078. Epub 2012 Oct 25.PMID: 23133550 Free PMC article.

The use of satellite data to measure ultraviolet-B penetrance and its potential association with age of multiple sclerosis onset.

Amram O, Schuurman N, Randall E, Zhu F, Saeedi J, Rieckmann P, Yee I, Tremlett H.Mult Scler Relat Disord. 2018 Apr;21:30-34. doi: 10.1016/j.msard.2018.02.005. Epub 2018 Feb 6.PMID: 29455071

Multiple sclerosis update.

Markowitz CE.Am J Manag Care. 2013 Nov;19(16 Suppl):s294-300.PMID: 24494618 Review.


Cited by

Environmental Influences on Risk and Disease Course in Pediatric Multiple Sclerosis.

Dinov D, Brenton JN.Semin Pediatr Neurol. 2023 Jul;46:101049. doi: 10.1016/j.spen.2023.101049. Epub 2023 Apr 25.PMID: 37451747

The Role of Vitamin D in Neuroprotection in Multiple Sclerosis: An Update.

Sangha A, Quon M, Pfeffer G, Orton SM.Nutrients. 2023 Jun 30;15(13):2978. doi: 10.3390/nu15132978.PMID: 37447304 Free PMC article. Review.

Autoreactive lymphocytes in multiple sclerosis: Pathogenesis and treatment target.

Liu R, Du S, Zhao L, Jain S, Sahay K, Rizvanov A, Lezhnyova V, Khaibullin T, Martynova E, Khaiboullina S, Baranwal M.Front Immunol. 2022 Sep 23;13:996469. doi: 10.3389/fimmu.2022.996469. eCollection 2022.PMID: 36211343 Free PMC article. Review.

Prevalence of chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy in two regions of Australia.

Park SB, Li T, Kiernan MC, Garg N, Wilson I, White R, Boggild M, McNabb A, Lee-Archer M, Taylor BV.Muscle Nerve. 2022 Nov;66(5):576-582. doi: 10.1002/mus.27698. Epub 2022 Aug 29.PMID: 36054471 Free PMC article.

Developing a clinical-environmental-genotypic prognostic index for relapsing-onset multiple sclerosis and clinically isolated syndrome.

Fuh-Ngwa V, Zhou Y, Charlesworth JC, Ponsonby AL, Simpson-Yap S, Lechner-Scott J, Taylor BV; AusLong/Ausimmune Investigators Group.Brain Commun. 2021 Dec 4;3(4):fcab288. doi: 10.1093/braincomms/fcab288. eCollection 2021.PMID: 34950873 Free PMC article.


KMEL References